中华放射医学与防护杂志
中華放射醫學與防護雜誌
중화방사의학여방호잡지
Chinese Journal of Radiological Medicine and Protection
2015年
4期
299-302
,共4页
汤敏敏%刘建中%武志芳%陆克义%李思进%高永举%武新宇%徐俊玲
湯敏敏%劉建中%武誌芳%陸剋義%李思進%高永舉%武新宇%徐俊玲
탕민민%류건중%무지방%륙극의%리사진%고영거%무신우%서준령
分化型甲状腺癌%131I%放射性活度%尿液%剂量当量率
分化型甲狀腺癌%131I%放射性活度%尿液%劑量噹量率
분화형갑상선암%131I%방사성활도%뇨액%제량당량솔
Differentiated thyroid cancer%131I%Radioactivity%Urine%Equivalent dose rate
目的 评估分化型甲状腺癌(DTC)患者131I治疗后体内残留放射性活度.方法 本次前瞻性研究包括49例DTC患者,分为“清甲”(131I摧毁术后残留的甲状腺组织)与“清灶”(131I治疗甲状腺床残留甲状腺癌、甲状腺床复发灶和转移灶)组,于服131I后收集患者每次排泄尿液,测定患者每天每次通过尿液排泄的放射性活度及排泄的总放射性活度,进而估算患者体内残留的放射性活度.分别于服131I后2、6、24、48、72 h进行1 m处剂量当量率的测定,估算患者体内残留放射性活度达到400 MBq时1 m处剂量当量率.结果 服131I后2、6、24、48、72 h体内残留131I活度占服131I初始活度的百分比,“清甲”组分别为99%、72%、25%、15%、7%,1 m处剂量当量率分别为157、120、35、11、9 μSv/h;“清灶”组对应百分比分别为99%、71%、18%、7%、3%,1 m处剂量当量率分别为232、182、48、11、2 μSv/h.体内残留的放射性活度与1 m处剂量当量率呈正相关(r=0.94,P <0.001).“清甲”与“清灶”组服131I后48 ~ 72 h体内残留放射性活度分别为548~ 259及451~248 MBq,对应的1 m处剂量当量率为8~ 10μSv/h.结论 DTC患者于服131I后48 ~ 72 h体内残留放射性活度达到国家标准规定的400 MBq,即DTC患者1 m处剂量当量率达到8~ 10μSv/h方可出院.
目的 評估分化型甲狀腺癌(DTC)患者131I治療後體內殘留放射性活度.方法 本次前瞻性研究包括49例DTC患者,分為“清甲”(131I摧燬術後殘留的甲狀腺組織)與“清竈”(131I治療甲狀腺床殘留甲狀腺癌、甲狀腺床複髮竈和轉移竈)組,于服131I後收集患者每次排洩尿液,測定患者每天每次通過尿液排洩的放射性活度及排洩的總放射性活度,進而估算患者體內殘留的放射性活度.分彆于服131I後2、6、24、48、72 h進行1 m處劑量噹量率的測定,估算患者體內殘留放射性活度達到400 MBq時1 m處劑量噹量率.結果 服131I後2、6、24、48、72 h體內殘留131I活度佔服131I初始活度的百分比,“清甲”組分彆為99%、72%、25%、15%、7%,1 m處劑量噹量率分彆為157、120、35、11、9 μSv/h;“清竈”組對應百分比分彆為99%、71%、18%、7%、3%,1 m處劑量噹量率分彆為232、182、48、11、2 μSv/h.體內殘留的放射性活度與1 m處劑量噹量率呈正相關(r=0.94,P <0.001).“清甲”與“清竈”組服131I後48 ~ 72 h體內殘留放射性活度分彆為548~ 259及451~248 MBq,對應的1 m處劑量噹量率為8~ 10μSv/h.結論 DTC患者于服131I後48 ~ 72 h體內殘留放射性活度達到國傢標準規定的400 MBq,即DTC患者1 m處劑量噹量率達到8~ 10μSv/h方可齣院.
목적 평고분화형갑상선암(DTC)환자131I치료후체내잔류방사성활도.방법 본차전첨성연구포괄49례DTC환자,분위“청갑”(131I최훼술후잔류적갑상선조직)여“청조”(131I치료갑상선상잔류갑상선암、갑상선상복발조화전이조)조,우복131I후수집환자매차배설뇨액,측정환자매천매차통과뇨액배설적방사성활도급배설적총방사성활도,진이고산환자체내잔류적방사성활도.분별우복131I후2、6、24、48、72 h진행1 m처제량당량솔적측정,고산환자체내잔류방사성활도체도400 MBq시1 m처제량당량솔.결과 복131I후2、6、24、48、72 h체내잔류131I활도점복131I초시활도적백분비,“청갑”조분별위99%、72%、25%、15%、7%,1 m처제량당량솔분별위157、120、35、11、9 μSv/h;“청조”조대응백분비분별위99%、71%、18%、7%、3%,1 m처제량당량솔분별위232、182、48、11、2 μSv/h.체내잔류적방사성활도여1 m처제량당량솔정정상관(r=0.94,P <0.001).“청갑”여“청조”조복131I후48 ~ 72 h체내잔류방사성활도분별위548~ 259급451~248 MBq,대응적1 m처제량당량솔위8~ 10μSv/h.결론 DTC환자우복131I후48 ~ 72 h체내잔류방사성활도체도국가표준규정적400 MBq,즉DTC환자1 m처제량당량솔체도8~ 10μSv/h방가출원.
Objective To estimate the residual activity in patients with differentiated thyroid cancer (DTC) after administration of 131I for post-operative therapy.Methods Forty-nine DTC patients were divided into two groups (thyroid remnant 131I ablation therapy group and group with 131I treatment for recurrent and metastatic lesions).Urine excretion of 49 patients with differentiated thyroid cancer after 131I therapy was collected every time,with the activity of urine excretion and total activity calculated,and then residual activity in patients estimated.The determination of equivalent dose rate at 1 meter point were performed to estimate multi-temporal residual activity in each patient at 2,6,24,48,and 72 h after administration of therapeutic doses of 131I,respectively.The equivalent dose rate at 1 meter point was indirectly estimated when the residual activity reach to 400 MBq.Correlation and regression were used to evaluate the relationship between residual activity and the equivalent dose rate at 1 m.Results The percentage of residual activity at 2,6,24,48,and 72 h after administration of 131I,was,respectively,99%,72%,25%,15% and 7% in patients who have undergone thyroid remnant 131I ablation,and 99%,71%,18%,7% and 3% in those who have undergone 131I treatment for metastatic lesions.The equivalent dose rate at 1 m point was,respectively,157,120,35,11 and 9 μSv/h in the former and 232,182,48,11 and 2 μSv/h in the latter.There is a positive correlation between residual activity and equivalent dose rate at 1 m (r =0.94,P < 0.001).The residual activity at 48-72 h after administration of 131I was,respectively,548-259 MBq in the former and 451-248 MBq in the latter.The corresponding equivalent dose rate at 1 m ranged from 8 to 10 μSv/h.Conclusions The in vivo residual activity reaches the national standard of 400 MBq (10.8 mCi) in patients with differentiated thyroid cancer during 48-72 h after administration of 131I and the equivalent dose rate at 1 m ranged from 8 to 10 μSv/h.At this time,radiation isolation could be released.